Administrative Core

行政核心

• 批准号: 10259873
• 负责人: Kevin D Cooper
• 金额: $ 33.14万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-20 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10259873
• 关键词: Accountability; Achievement; Advisory Committees; Area; Artificial Intelligence; Bioinformatics; Clinical Data; Clinical Research; Communities; Computational algorithm; Computerized Medical Record; Core Facility; Cutaneous; Data; Data Set; Databases; Dermatology; Development; Electronic Health Record; Environment; Goals; Health Care Research; Healthcare; Healthcare Systems; Hospitals; Human; Human Experimentation; Infrastructure; Leadership; Machine Learning; Medical center; Methodology; Mission; Modeling; Mus; Pathway interactions; Patients; Pharmaceutical Preparations; Pre-Clinical Model; Process; Provider; Psoriasis; Research; Research Personnel; Research Project Grants; Resources; Role; Scientist; System; Talents; Techniques; Technology; Testing; Translating; Translational Research; University Hospitals; Unmarried person; Validation; Work; clinical application; clinical phenotype; cohort; comorbidity; data mining; decision making algorithm; design; experience; individual patient; innovation; innovative technologies; new technology; novel; programs; recruit; symposium

The mission of the CORT is to advance therapy for psoriasis and related comorbidities by leveraging new bioinformatic methodologies with well-developed murine and human experimentation capabilities. This technology concatenation is expected to more nimbly translate new scientific opportunities into clinical applications. The CORT Administrative Core (AC) proposes to manage an innovative model wherein a collaborative research project (CRP) will serve as the central hub that will iterate significant bi-directional work from 2 highly interactive research cores to experimentally test hypotheses and newly identified pathway specific and repurposed FDA drug leads. The AC will accomplish this goal through its Aims to: 1. Convene an Internal Advisory Committee and an External Advisory Board which a) develops and applies accountability metrics for the CRP, each Core, and the P&F projects, b) manages a Go-NoGo iterative algorithmic decision-making process regarding CORT resource utilization and c) coordinates patient cohort assets and regulatory compliance; 2. Provide fiscal management of the CORT; 3. Branch out exciting new developments deriving from CORT findings through a robust Pilot & Feasibility (P&F) program; 4. Organize and advertise Enrichment Activities that bring CORT and Community researchers together in scientific venues to exchange ideas and new technologies. The AC leadership will work closely not only with lab scientists, but also with the leadership and programmers of the CLEveland Area Research Platform for Advancing Translational Healthcare (CLEARPATH), a comprehensive research database with Limited Data Set contribution from all 3 major Cleveland healthcare systems. CLEARPATH will create connected data (e.g., Biospecimen results, EMR clinical phenotype, `Omics data) as well as a Single person record across the system, enabling research cohort discovery and validation across the aggregate dataset. This approach will allow us to preliminarily validate psoriasis cohort subsets, mix `omic pathways and drug leads identified by the Cores and CRP. In addition to its roles as an information conduit and facilitator for research, the AC also promotes the cutaneous research environment for psoriasis and its comorbid and related conditions through enrichment programs. As such, the AC is instrumental in the design and planning of research symposia, and recruiting potential P&F program recipients with innovative technologies and/or complementary research expertise to the CORT. The cross-disciplinary approach of combining a Preclinical Modeling Core (PMC) with an Applied Meta `Omics Core (AMC) that takes advantage of artificial intelligence, data mining, network techniques and machine learning to query available interaction networks and highly annotated integrated electronic medical records (EMRi) is highly innovative. The active engagement of the AC will be instrumental for the successful achievement of the broader goal of identifying new psoriasis pathways and repurposed approved drugs.

CORT 的使命是利用新疗法推进银屑病及相关合并症的治疗 具有发达的小鼠和人体实验能力的生物信息方法。这 技术串联有望更灵活地将新的科学机会转化为临床 应用程序。 CORT 管理核心 (AC) 提议管理一个创新模型，其中 合作研究项目（CRP）将作为中心枢纽，迭代重要的双向研究 通过 2 个高度互动的研究核心开展工作，通过实验检验假设和新发现​​的假设 途径特异性和重新利用的 FDA 药物先导化合物。审计委员会将通过以下目标实现这一目标： 1. 召集内部咨询委员会和外部咨询委员会，a) 制定并应用 CRP、每个核心以及 P&F 项目的问责制指标，b) 管理 Go-NoGo 迭代 关于 CORT 资源利用的算法决策过程和 c) 协调患者队列 资产和监管合规性； 2. 提供CORT的财务管理； 3. 拓展令人兴奋的新内容 通过强大的试点和可行性 (P&F) 计划从 CORT 发现中得出的发展； 4. 组织 并宣传将 CORT 和社区研究人员聚集在科学场所的丰富活动 交流想法和新技术。 AC 领导层不仅将与实验室科学家密切合作，还将与领导层和 克利夫兰地区推进转化医疗保健研究平台的程序员 (CLEARPATH)，一个综合研究数据库，所有 3 个专业的数据集贡献有限 克利夫兰医疗保健系统。 CLEARPATH 将创建连接数据（例如，生物样本结果、EMR 临床表型、“组学数据”以及整个系统中的单人记录，使研究队列成为可能 跨聚合数据集的发现和验证。这个方法可以让我们初步验证 银屑病队列子集、混合组学途径以及核心和 CRP 确定的药物先导化合物。此外 作为信息渠道和研究促进者的角色，AC 还促进皮肤研究 通过强化计划了解银屑病及其合并症和相关病症的环境。因此， AC 在研究研讨会的设计和规划以及招募潜在的 P&F 项目方面发挥了重要作用 拥有创新技术和/或与 CORT 互补的研究专业知识的接收者。 将临床前建模核心 (PMC) 与应用元相结合的跨学科方法 `Omics Core（AMC）利用人工智能、数据挖掘、网络技术和 机器学习来查询可用的交互网络和高度注释的集成电子医疗 记录（EMRi）具有高度创新性。审计委员会的积极参与将有助于会议的成功 实现确定新的银屑病途径和重新利用已批准药物的更广泛目标。